4/A: Stepan Co. Corrects Executive Stock Award Filing

Sean T. Moriarty, VP & GM of Surfactants at Stepan Co., filed an amendment to correct the exercise price of previously reported stock appreciation rights.

Summary

• This Form 4/A amends an original filing from March 4, 2026, regarding equity compensation for Sean T. Moriarty.
• The primary correction involves the exercise price of Stock Appreciation Rights (SARs) granted on March 2, 2026.
• The exercise price was corrected from $17.47 to $50.06 due to an administrative error.
• The filing confirms the acquisition of 56.765 shares of common stock at $52.51 per share on February 27, 2026.
• The reporting person holds 14,205.2335 shares directly and 4,478.351 shares indirectly via an ESOP II Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative correction that does not impact the company's financial outlook or operational strategy.

Positives

• The amendment demonstrates transparency and regulatory compliance by proactively correcting an administrative error.

Negatives

• The filing highlights an administrative error in the original reporting of executive compensation data.

Risks

• Internal control weaknesses regarding the accurate reporting of executive equity compensation.

Future Outlook

The filing outlines future vesting schedules for equity awards, with SARs and RSUs vesting ratably over three years beginning March 2, 2027, and performance shares subject to goals through December 31, 2028.

Management Comments

• The amendment corrects the reported conversion/exercise price; no other aspects of the reported transaction are affected.

Industry Context

StockSavvy.ai notes that administrative amendments to executive compensation filings are common and generally do not reflect underlying business performance or strategic shifts.

Comparison to Industry Standards

• The reporting of equity compensation follows standard SEC disclosure requirements for publicly traded companies.
• The use of SARs and performance-based equity is consistent with standard executive compensation packages in the chemical manufacturing sector.

Stakeholder Impact

• Minimal impact on shareholders as this is a corrective filing regarding executive compensation reporting.

Next Steps

• Vesting of SARs and RSUs beginning March 2, 2027.
• Certification of performance goals for performance shares following the period ending December 31, 2028.

Key Dates

Keywords

Stepan Co, SCL, Form 4/A, Executive Compensation, Stock Appreciation Rights, Insider Trading